This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
NCT ID: NCT00047840
Last Updated: 2016-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
129 participants
INTERVENTIONAL
2002-10-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00071188
ZD6474 in Treating Patients With Small Cell Lung Cancer
NCT00066313
Phase II Study of ZD6474 in Advanced NSCLC
NCT00290537
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
NCT00364351
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
NCT00021008
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZD6474
Placebo
Docetaxel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failure of first-line platinum-based chemotherapy
Exclusion Criteria
* Bronchoalveolar carcinoma
* Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)
* Prior treatment with docetaxel
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Sciences & Operations
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Los Angeles, California, United States
Research Site
Jacksonville, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Boston, Massachusetts, United States
Research Site
Pittsfield, Massachusetts, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Billings, Montana, United States
Research Site
Great Neck, New York, United States
Research Site
New York, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Coos Bay, Oregon, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Houston, Texas, United States
Research Site
Brno, , Czechia
Research Site
Chomutov, , Czechia
Research Site
Hradec, , Czechia
Research Site
Ostrava, , Czechia
Research Site
Pilsen, , Czechia
Research Site
Prague, , Czechia
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Deszk, , Hungary
Research Site
Törökbálint, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6474IL/0006
Identifier Type: -
Identifier Source: org_study_id
NCT00054093
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.